Experience

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics, Inc. of shares of its common stock for up to a maximum offering…

Davis Polk advised the underwriters on an SEC-registered offering by BankUnited, Inc. of $300 million aggregate principal amount of 5.125% subordinated notes due 2030.BankUnited, Inc…

Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend Biotech Corporation of 21,188,750 American Depositary Shares, each…

Davis Polk advised the representative of the several underwriters in connection with an underwritten secondary offering of 14,130,523 shares of common stock of Werner Enterprises, Inc. by…

Davis Polk advised the joint book-running managers in connection with the $212 million SEC-registered follow-on offering of 2,995,757 shares of Class A common stock of Hamilton Lane…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by HubSpot, Inc. of $460 million aggregate principal amount of its 0.375% convertible senior notes due 2025…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Datadog, Inc. of $747.5 million aggregate principal amount of its 0.125%…

Davis Polk advised the representatives of the underwriters in connection with the $70 million follow-on public offering of 5,000,000 shares of common stock of TransMedics Group, Inc…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Under Armour, Inc. of $440 million aggregate principal amount of its 1.500%…